Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, Sydney, NSW, Australia.
School of Medical Sciences (Pharmacology), Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Lancet Oncol. 2014 Oct;15(11):e493-503. doi: 10.1016/S1470-2045(14)70263-3.
Inflammation is a recognised hallmark of cancer that substantially contributes to the development and progression of malignancies. In established cancers, there is increasing evidence for the roles that local immune response and systemic inflammation have in progression of tumours and survival of patients with cancer. This knowledge provides an opportunity to target these inflammatory responses to improve patient outcomes. In this Review, we examine the complex interplay between local immune responses and systemic inflammation, and their influence on clinical outcomes, and propose potential anti-inflammatory interventions for patients with cancer.
炎症是癌症的一个公认特征，它在恶性肿瘤的发生和发展中起着重要作用。在已确立的癌症中，越来越多的证据表明局部免疫反应和全身炎症在肿瘤的进展和癌症患者的生存中起着作用。这一知识为靶向这些炎症反应以改善患者预后提供了机会。在这篇综述中，我们研究了局部免疫反应和全身炎症之间的复杂相互作用，以及它们对临床结果的影响，并为癌症患者提出了潜在的抗炎干预措施。
Lancet Oncol. 2014-10
Eur Urol. 2012-10-17
Clin Transl Oncol. 2025-8-19
Transl Gastroenterol Hepatol. 2025-4-23
Zotero 插件